Clinical Trials in China / NCT05965362
Recruiting
Observational
Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）
NCT05965362 · tracked via the Priya Life Science China tracker
Condition(s) studied
Infective Endocarditis
Investigational drug(s) / intervention(s)
Observational; No Interventions were given.
Observational; No Interventions were given.: Observational; No Interventions were given.
Study summary
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Eligibility
Inclusion Criteria:
* Patients with clinically confirmed infective endocarditis
Exclusion Criteria:
* Patients refuse to sign informed consent form
* Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Primary outcome measure(s)
- Change in the incidence of MACCE — 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| First Affiliated Hospital of Xian Jiantong University | Xi'an | Shaanxi | Recruiting |
More First Affiliated Hospital Xi'an Jiaotong University trials in China
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05965362 on ClinicalTrials.gov ↗ ← All trials in China